J 2018

Colicin F-Y inhibits pathogenic Yersinia enterocolitica in mice

BOSÁK, Juraj, Lenka MICENKOVÁ, Matěj HRALA, Katarína POMORSKÁ, Michaela BOSÁKOVÁ et. al.

Basic information

Original name

Colicin F-Y inhibits pathogenic Yersinia enterocolitica in mice

Authors

BOSÁK, Juraj (703 Slovakia, belonging to the institution), Lenka MICENKOVÁ (703 Slovakia, belonging to the institution), Matěj HRALA (203 Czech Republic, belonging to the institution), Katarína POMORSKÁ (703 Slovakia, belonging to the institution), Michaela BOSÁKOVÁ (203 Czech Republic, belonging to the institution), Pavel KREJČÍ (203 Czech Republic, belonging to the institution), Eduard GÖPFERT (203 Czech Republic), Martin FALDYNA (203 Czech Republic) and David ŠMAJS (203 Czech Republic, guarantor, belonging to the institution)

Edition

Scientific reports, London, NATURE PUBLISHING GROUP, 2018, 2045-2322

Other information

Language

English

Type of outcome

Článek v odborném periodiku

Field of Study

10601 Cell biology

Country of publisher

United Kingdom of Great Britain and Northern Ireland

Confidentiality degree

není předmětem státního či obchodního tajemství

Impact factor

Impact factor: 4.011

RIV identification code

RIV/00216224:14110/18:00101322

Organization unit

Faculty of Medicine

UT WoS

000441775900006

Keywords in English

Yersinia enterocolitica; Colicin F-Y

Tags

International impact, Reviewed
Změněno: 26/3/2019 10:26, Soňa Böhmová

Abstract

V originále

Yersiniosis belongs to the common foodborne diseases around the world, and frequently manifests as diarrhea that can be treated with probiotics. Colicin F-Y is an antibacterial agent produced by bacteria and it is capable of specific growth inhibition of Yersinia enterocolitica, the causative agent of gastrointestinal yersiniosis. In this study, recombinant E. coli producing colicin F-Y were constructed, using both known probiotic strains EcH22 and EcColinfant, and the newly isolated murine strains Ec1127 and Ec1145. All E. coli strains producing colicin FY inhibited growth of pathogenic Y. enterocolitica during co-cultivation in vitro. In dysbiotic mice treated with streptomycin, E. coli strains producing colicin F-Y inhibited progression of Y. enterocolitica infections. This growth inhibition was not observed in mice with normal gut microflora, likely due to insufficient colonization capacity of E. coli strains and/or due to spatial differences in intestinal niches. Isogenic Y. enterocolitica producing colicin F-Y was constructed and shown to inhibit pathogenic Y. enterocolitica in mice with normal microflora. Evidence of in vivo antimicrobial activity of colicin F-Y may have utility in the treatment of Y. enterocolitica infections.

Links

EF16_013/0001761, research and development project
Name: RECETOX RI
GA16-21649S, research and development project
Name: Molekulární charakterizace nových bakteriocinů identifikovaných v rodech Escherichia a Shigella
Investor: Czech Science Foundation
LM2015051, research and development project
Name: Centrum pro výzkum toxických látek v prostředí (Acronym: RECETOX RI)
Investor: Ministry of Education, Youth and Sports of the CR
ROZV/25/LF/2017, interní kód MU
Name: LF - Příspěvek na IP 2017
Investor: Ministry of Education, Youth and Sports of the CR, Internal development projects